Impact of COVID-19 on Patient-Initiated Discontinuation of Omalizumab in Two Academic Hospital Clinics at the University of Toronto

Abstract

Keywords

COVID-19 omalizumab dermatology asthma urticaria

Get full access to this article

View all access options for this article.

References

Thomson

NC.

Chaudhuri

. Omalizumab: clinical use for the management of asthma. Clin Med Insights Circ Respir Pulm Med. 2012;6:27-40.doi:10.4137/CCRPM.S7793

http://www.ncbi.nlm.nih.gov/pubmed/22745565

Kaplan

AP.

Giménez-Arnau

AM.

Saini

. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72(4):519-533.doi:10.1111/all.13083

http://www.ncbi.nlm.nih.gov/pubmed/27861988

World Health Organization . Canada: WHO Coronavirus Disease (COVID-19) Dashboard. Accessed May 27, 2020. https://covid19.who.int/region/amro/country/ca

Tan

RA.

Corren

. Safety of omalizumab in asthma. Expert Opin Drug Saf. 2011;10(3):463-471.doi:10.1517/14740338.2011.563840

http://www.ncbi.nlm.nih.gov/pubmed/21401438

Esquivel

Busse

WW.

Calatroni

et al. Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma. Am J Respir Crit Care Med. 2017;196(8):985-992.doi:10.1164/rccm.201701-0120OC

http://www.ncbi.nlm.nih.gov/pubmed/28608756